Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 4, 2006, Pages 370-378

  Lee, Seung Ha ^b   Rhim, TaiYoun ^b   Choi, Yun Sung ^b   Min, Ji Won ^b   Kim, Sung Ho ^b   Cho, Sun Young ^b   Paik, Young Ki ^b   Park, Choon Sik ^a  

^a Soonchunhyang University   (South Korea)

^b NONE

Author keywords

Aspirin induced asthma; Complement C3a and C4a; Two dimensional electrophoresis

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; APOLIPOPROTEIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A;

ADULT; AMINO ACID SEQUENCE; ARTICLE; ASPIRIN INDUCED ASTHMA; ASTHMA; CLINICAL ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; UPREGULATION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ASTHMA; COMPLEMENT C3A; COMPLEMENT C4A; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEOMICS;

EID: 32444444835     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200505-740OC     Document Type: Article

References (52)

1. Samter M, Beers RF. Concerning the nature of intolerance to aspirin. J Allergy 1967;40:281-293.
2. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003;111:913-921.
3. Picado C. Aspirin-intolerant asthma: role of cyclo-oxygenase enzymes. Allergy 2002;S72:58-60.
4. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990;3:588-593.
5. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ 1975;1:67-69.
6. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-697.
7. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990;323:645-655.
8. Hui Y, Funk CD. Cysteinyl leukotriene receptors. Biochem Pharmacol 2002;64:1549-1557.
9. Sanak M, Sampson AP. Biosynthesis of cysteinyl-leukotrienes in aspirin intolerant asthma. Clin Exp Allergy 1999;29:306-313.
10. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999;104:5-13.
11. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990;323:645-655.
12. Arm JP, Austen KF. Leukotriene receptors and aspirin sensitivity. N Engl J Med 2002;347:1524-1526.
13. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002;347:1493-1499.
14. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J Allergy Clin Immunol 1998;102:50-56.
15. Holgate ST, Sampson AP. Antileukotriene therapy: future directions. Am J Respir Crit Care Med 2000;161:147-153.
16. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A, Lam BK, Penrose JF, Austen KF, Holgate ST, et al. Overexpression of leukotriene C(4) synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101:834-846.
17. Babu KS, Salvi SS. Aspirin and asthma. Chest 2000;118:1470-1476.
18. Szczeklik A, Sanak M. Genetic mechanisms in aspirin-induced asthma. Am J Respir Crit Care Med 2000;161:S142-S146.
19. American Thoracic Society. Standards for the diagnosis and treatment of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1989;136:225-244.
20. National Institutes of Health. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. Bethesda, MD: National Heart, Lung, and Blood Institute; 2002. Publication No. 02-3659.
21. Chai H, Farr RS, Froehlich LA, Mathison DA, McLean JA, Rosenthal RR, Sheffer AL, Spector SL, Townley RG. Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol 1975;56:323-327.
22. Park CS, Kim YY, Kang SY. Correlation between RAST and skin test for inhalant offending allergens. J Korean Soc Allergol 1984;3:1-9.
23. Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000;15:863-869.
24. Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, Pognan F, Hawkins E, Currie I, Davison M. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001;1:377-396.
25. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68:850-858.
26. Beavis RC, Chait BT. α-Cyano-4-hydroxycinnamic acid as a matrix for matrix assisted laser desorption mass spectrometry. Org Mass Spectrom 1992;27:156-158.
27. Vorm O, Roepstorff P, Mann M. Improved resolution and very high sensitivity in MALDI TOF of matrix surfaces made by fast evaporation. Anal Chem 1994;66:3281-3287.
28. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ 1975;1:67-69.
29. Aarons L, Clifton P, Fleming G, Rowland M. Aspirin binding and the effect of albumin on spontaneous and enzyme-catalysed hydrolysis. J Pharm Pharmacol 1980;32:537-543.
30. Williams WR, Pawlowicz A, Davies BH. In vitro tests for the diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1990;86:445-451.
31. Celiker V, Basgul E. Anaesthesia in aspirin-induced asthma. Allergol Immunopathol (Madr) 2003;31:338-341.
32. Tokizawa M, Takizawa J, Nagano S, Takahashi T. Serum high density lipoprotein cholesterol levels in patients with bronchial asthma. Nihon Kyobu Shikkan Gakkai Zasshi 1985;23:98-105.
33. Horani MH, Gobal F, Haas MJ, Wong NC, Mooradian AD. Cyclooxygenase inhibition is associated with downregulation of apolipoprotein AI promoter activity in cultured hepatoma cell line HepG2. Metabolism 2004;53:174-181.
34. Akaike M, Azuma H, Kagawa A, Matsumoto K, Hayashi I, Tamura K, Nishiuchi T, Iuchi T, Takamori N, Aihara K, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002;48:1454-1459.
35. Hugli TE. The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a. Crit Rev Immunol 1981;1:321-366.
36. Kosmas EN, Zorpidou D, Vassilareas V, Roussou T, Michaelides S. Decreased C4 complement component serum levels correlate with the degree of emphysema in patients with chronic bronchitis. Chest 1997;112:341-347.
37. Chauhan S, Gupta MK, Goyal A, Dasgupta DJ. Alterations in immunoglobulin and complement levels in chronic obstructive pulmonary disease. Indian J Med Res 1990;92:241-245.
38. Bautsch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raschke U, Ames RS, Sohns B, Flemme N, Meyer zu Vilsendorf A, Grove M, et al. Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol 2000;165:5401-5405.
39. Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, McCray PB, Tack BF, Wetsel RA. Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 2001;166:2025-2032.
40. Gerard NP, Gerard C. Complement in allergy and asthma. Curr Opin Immunol 2002;14:705-708.
41. Daffern PJ, Pfeifer PH, Ember JA, Hugli TE. C3a is a chemotaxin for human eosinophils but not for neutrophils: I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995;181:2119-2127.
42. Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD, Siegbahn A, Murphy PM. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 1996;157:1693-1698.
43. Takafuji S, Tadokoro K, Ito K, Dahinden CA. Degranulation from human eosinophils stimulated with C3a and C5a. Int Arch Allergy Immunol 1994;104:27-29.
44. el-Lati SG, Dahinden CA, Church MK. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol 1994;02:803-806.
45. Hansch GM, Voigtlander V, Rother U. Effect of aspirin on the complement system in vitro. Int Arch Allergy Appl Immunol 1980;61:150-158.
46. Runmore MM, Aron SM, Hiross EJ. A review of mechanism of action of aspirin and its potential as an immunomodulating agent. Med Hypotheses 1987;22:387-400.
47. Stimler NP, Bloor CM, Hugli TE. C3a-induced contraction of guinea pig lung parenchyma: role of cyclooxygenase metabolites. Immunopharmacology 1983;5:251-257.
48. Minta JO, Urowitz MB, Smythe HA, Isenman DE. Effect on the human complement system of the major non-steroidal anti-inflammatory drugs: aspirin, indomethacin, phenylbutazone, oxyphenbutazone and sulindac. Clin Exp Immunol 1983;53:555-561.
49. Sainte-Laudy J. Acetylsalicylic acid: hypersensitivity, intolerance, or allergy? Allerg Immunol (Paris) 2001;33:120-126.
50. Hansch GM, Voigtlander V, Rother U. Effect of aspirin on the complement system in vitro. Int Arch Allergy Appl Immunol 1980;61:150-158.
51. Pleskow WW, Chenoweth DE, Simon RA, Stevenson DD, Curd JG. The absence of detectable complement activation in aspirin-sensitive asthmatic patients during aspirin challenge. J Allergy Clin Immunol 1983;72:462-468.
52. Delaney JC, Kay AB. Complement components and IgE in patients with asthma and aspirin idiosyncrasy. Thorax 1976;31:425-427.